Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
AGIO
AGIO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AGIO News
Agios Advances Accelerated Approval for Mitapivat in Sickle Cell Disease
21h ago
NASDAQ.COM
Agios Secures FDA Priority Review for Sickle Cell Therapy
21h ago
stocktwits
Agios Pharmaceuticals Shares Surge on Positive FDA News
21h ago
Fool
Agios Pharmaceuticals Receives FDA Priority Review for Pyrukynd Expansion
1d ago
seekingalpha
Agios Pharmaceuticals Receives FDA Priority Review for Mitapivat
1d ago
NASDAQ.COM
Small-Cap Stocks Set for Best Performance in 30 Years
Jun 25 2026
CNBC
Mitapivat Shows Significant Hemoglobin Improvement in Sickle Cell Disease
Jun 13 2026
Newsfilter
Agios Pharmaceuticals Enters Exclusive License Agreement with Oscotec for Cevidoplenib
Jun 01 2026
NASDAQ.COM
Agios Secures Exclusive Global Rights to Novel SYK Inhibitor
Jun 01 2026
Newsfilter
Regulatory Approvals and Collaborations in Biotech Sector
May 29 2026
NASDAQ.COM
Agios Pharmaceuticals Halts Blood Cancer Treatment Trials
May 29 2026
seekingalpha
Agios Halts Development of LR-MDS Drug Tebapivat
May 29 2026
Newsfilter
Agios Receives EU Approval for PYRUKYND
May 26 2026
NASDAQ.COM
Avanzanite Launches PYRUKYND in the EU
May 22 2026
Newsfilter
PYRUKYND Approved in EU for Thalassemia Treatment
May 22 2026
Newsfilter
Agios Pharmaceuticals Presents New Data on Mitapivat at EHA 2026
May 12 2026
Newsfilter
Show More News
